Jessica Hergert

Assistant Editor, OncLive®
Jessica joined the company in August 2019 and is one of the point contacts for the OncLive On Air™ podcast. She is a Rider University alumna and holds a degree in journalism and biology. Prior to joining MJH Life Sciences, she interned with the Ireland-based social media monitoring agency Olytico and served as a copy editor and writer for The Rider News. Email: jhergert@onclive.com

Articles

Positive Data With Parsaclisib/Ruxolitinib Pave the Way for Phase 3 Studies in Myelofibrosis

May 26th 2021

Abdulraheem Yacoub, MD, discusses the rationale for combining PI3K inhibitors with ruxolitinib in myelofibrosis, the results of the phase 2 study with parsaclisib, and ongoing phase 3 trials evaluating this novel combination.

Routine Screening Rates for Breast, Colorectal, and Prostate Cancers Decline During COVID-19 Pandemic

May 25th 2021

Screenings for breast cancer, colorectal cancer, and prostate cancer declined sharply from March to May 2020 vs the same time span in 2019, suggesting that public health efforts, such as increased use of screening modalities that do not require a procedure, are needed to address the deficit caused by the COVID-19 pandemic.

High TMB Fails to Show Predictive Biomarker Potential for Checkpoint Inhibition Across Cancers

May 24th 2021

High tumor mutational burden was useful in predicting clinical responses to checkpoint inhibitors in patients with certain cancer subtypes; however, TMB-H failed to demonstrate utility as a biomarker for treatment with checkpoint inhibitors across all solid cancer types.

Lurbinectedin Adds Complexity to Second-line Treatment Selection in Extensive-Stage Small Cell Lung Cancer

May 20th 2021

Bruna Pellini, MD, discusses the current state of treatment in ES-SCLC, the importance of including a diverse and representative patient population in clinical trials, and ongoing research in ES-SCLC.

Modernized Clinical Trials Include Diverse Representation, Decentralization, and Real-World Data in Post–COVID-19 Era

May 18th 2021

Silver linings of the COVID-19 pandemic have opened the door for new opportunities for decentralized clinical trials and real-world data in a post–COVID-19 world.

Ibrutinib Plus Venetoclax Results in High Residual Disease Eradication in CLL Model

May 17th 2021

The combination of ibrutinib and venetoclax were found to act on distinct subpopulations of chronic lymphocytic leukemia that have different proliferative capacities in an ex vivo model of the disease, suggesting that the dual-targeted approach has the potential to eradicate residual disease in patients with CLL.

Zolbetuximab Plus EOX Improves Survival in Claudin 18.2+ Gastric/GEJ Cancers

May 17th 2021

The addition of the first-in-class chimeric monoclonal antibody zolbetuximab to frontline epirubicin, oxaliplatin, and capecitabine chemotherapy resulted in prolonged progression-free survival and overall survival compared with EOX alone in patients with advanced Claudin 18.2-positive gastric and gastroesophageal junction adenocarcinoma, according to the primary results of the phase 2 FAST trial.

EGFR-Mutant NSCLC Landscape Evolves Among Adjuvant Approaches and Emerging Agents

May 14th 2021

Joshua M. Bauml, MD, discusses the use of osimertinib in EGFR-mutant NSCLC, the utility of the agent as adjuvant therapy, and emerging targeted agents for patients with EGFR exon 20 insertions.

Ixazomib/Ibrutinib Combo Could Enhance Single-Agent BTK Inhibitor Efficacy in Relapsed/Refractory MCL

May 13th 2021

The ongoing, phase 1/2 PrE0404 trial is evaluating the combination of ixazomib and ibrutinib in patients with relapsed/refractory mantle cell lymphoma with the goal of improving upon single-agent BTK inhibitor therapy in this patient population.

High Pretreatment ctDNA Levels Correlate With Short Diagnosis-to-Treatment Intervals in DLBCL

May 12th 2021

Pretreatment circulating tumor DNA levels were found to more objectively measure disease burden compared with diagnosis-to-treatment intervals in patients with diffuse large B-cell lymphoma and can therefore be used to quantify and mitigate selection bias in prospective DLBCL clinical trials.

An Expanding Armamentarium Calls for Tailored Therapy in Relapsed/Refractory Myeloma

May 12th 2021

The treatment paradigm for relapsed/refractory multiple myeloma has expanded rapidly with the recent integration of selinexor and BCMA-directed therapies, such as belantamab mafodotin-blmf and idecabtagene vicleucel.

Osimertinib Preferred in Adjuvant and Frontline Metastatic EGFR+ NSCLC, But More Therapies Are Needed to Overcome Resistance

May 11th 2021

Sherri Cervantez, MD, discusses the utility of osimertinib in non–small cell lung cancer, as well as remaining questions regarding the treatment of patients who develop resistance to the third-generation EGFR inhibitor.

Molecular Markers and Prior Treatment Inform Maintenance PARP Inhibition in Ovarian Cancer

May 11th 2021

Bradley J. Monk, MD, FACOG, FACS, discusses findings from key studies that solidified the role of PARP inhibition as maintenance therapy for patients with ovarian cancer, as well as guidelines for selecting PARP inhibitors alone or in combination with bevacizumab.

Adoption of BCMA-Directed CAR T-Cell Therapy Kickstarts A New Era in Multiple Myeloma

May 10th 2021

Nina Shah, MD, discusses the newfound role of BCMA-directed CAR T-cell therapies in multiple myeloma, how the field may select between ide-cel and cilta-cel if the latter is approved, and novel cellular therapies in clinical development.

NSCLC Paradigm Continues to Push Forward With Emerging Targets, but Predictive Biomarkers Are Limited

May 10th 2021

Nagashree Seetharamu, MD, MBBS, discusses emerging targets in non–small cell lung cancer and the limitations of current biomarkers.

Atezolizumab Plus Carboplatin Induces Early Efficacy Signals in Invasive Lobular Breast Cancer

May 7th 2021

Treatment with atezolizumab plus carboplatin demonstrated early clinical activity in patients with metastatic invasive lobular breast cancer, with slight trends toward increased clinical benefit in patients with triple-negative ILC and responders with higher PD-L1 expression, according to initial findings of the non-randomized phase 2 GELATO trial.

Multidisciplinary Care Is Paramount as New Therapies Emerge in Metastatic Pancreatic Cancer

May 6th 2021

Although the standard-of-care treatment for patients with metastatic pancreatic cancer remains largely unchanged with multi-agent chemotherapy, the role for multidisciplinary care has expanded significantly in recent years.

TRIM63 Is a Sensitive and Specific Biomarker That May Improve Diagnosis and Treatment Selection in RCC

May 5th 2021

The cancer-specific biomarker TRIM63 was highly expressed in all classes of microphthalmia-associated transcription factor family aberration–associated renal cell carcinoma compared with other subtypes of RCC, where TRIM63 expression was low or absent.

Navigating Neoadjuvant, Adjuvant Immunotherapy and ADCs in Metastatic TNBC

May 5th 2021

Although checkpoint inhibition has been shown to benefit some patients with metastatic triple-negative breast cancer, there is not yet a role for immune-based treatment in the neoadjuvant setting.

Primary Tumor Resection Plus Chemo is Not Recommended for Select Patients with Advanced CRC

May 5th 2021

Primary tumor resection followed by chemotherapy failed to demonstrate a survival benefit compared with chemotherapy alone in patients with stage IV colorectal cancer who have asymptomatic primary tumors and synchronous unresectable metastases, suggesting that PTR should no longer be considered a standard of care in this patient population.